IHS Chemical Week

People & Business :: M&A

Pfizer to Acquire King Pharmaceuticals for $3.6 Billion

1:06 AM MDT | October 13, 2010 | Deepti Ramesh

Pfizer says it has entered into a definitive agreement to acquire specialty pharmaceutical company King Pharmaceuticals (Bristol, TN) for $3.6 billion in cash, or $14.25/share, which represents a premium of about 40% to King's closing price on October 11. The acquisition is expected to be completed in the fourth quarter of 2010 or the first quarter of 2011. The acquisition will expand Pfizer's business profile, providing incremental diversified revenues generated by King's portfolio, including a prescription pharmaceutical business focused on formulations of pain...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa